Literature DB >> 29960007

Colistin resistance in carbapenemase-producing Klebsiella pneumoniae bloodstream isolates: Evolution over 15 years and temporal association with colistin use by time series analysis.

Giannoula S Tansarli1, Joseph Papaparaskevas2, Mina Balaska3, Michael Samarkos3, Angeliki Pantazatou1, Antonios Markogiannakis4, Marina Mantzourani3, Katerina Polonyfi3, George L Daikos5.   

Abstract

Colistin is often the only available treatment option against infections caused by carbapenemase-producing Klebsiella pneumoniae (CP-Kp). In this study, the evolution of colistin resistance among CP-Kp and its relationship with colistin use in a tertiary-care hospital in Athens, Greece, was investigated. All CP-Kp blood isolates recovered between January 2002 and June 2016 were tested for susceptibility to colistin by agar dilution and broth microdilution methods. Data on colistin use were collected from the pharmacy database. Time series of colistin use and resistance were analysed using the Box and Jenkins method. A transfer function model was built to quantify the dynamic relationship between colistin use and resistance. Overall, 313 CP-Kp isolates were identified. The percentage colistin resistance increased from 0% in 2002 to 26.9% in 2016 (R2 = 0.5, P < 0.01). A temporal association between colistin use and resistance was observed; an increase in colistin use by 1 DDD/100 patient-days led to a 0.05 increase in the incidence rate of colistin resistance. The time lag between the effect of colistin use on subsequent variations in colistin resistance was 3 months. Colistin use and prior levels of colistin resistance could explain 69% of colistin resistance; in the remaining 31%, other factors might have played a role. The results presented here demonstrate a significant temporal association between colistin use and colistin resistance. These findings have important implications in implementing strategies to contain colistin resistance.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bacteraemia; Colistin resistance; Colistin use; Klebsiella pneumoniae; Time series

Mesh:

Substances:

Year:  2018        PMID: 29960007     DOI: 10.1016/j.ijantimicag.2018.06.012

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  6 in total

Review 1.  Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Children.

Authors:  Kathleen Chiotos; Molly Hayes; Jeffrey S Gerber; Pranita D Tamma
Journal:  J Pediatric Infect Dis Soc       Date:  2020-02-28       Impact factor: 3.164

2.  Proteomic Changes of Klebsiella pneumoniae in Response to Colistin Treatment and crrB Mutation-Mediated Colistin Resistance.

Authors:  Lang Sun; Pernille Kronholm Rasmussen; Yinlei Bai; Xiulan Chen; Tanxi Cai; Jifeng Wang; Xiaojing Guo; Zhensheng Xie; Xiang Ding; Lili Niu; Nali Zhu; Xuefu You; Finn Kirpekar; Fuquan Yang
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

3.  Quantifying the effect of in-hospital antimicrobial use on the development of colistin-resistant Acinetobacter baumannii strains: a time series analysis.

Authors:  Rania Kousovista; Christos Athanasiou; Konstantinos Liaskonis; Olga Ivopoulou; Vangelis D Karalis
Journal:  Eur J Hosp Pharm       Date:  2022-03

Review 4.  NDM Metallo-β-Lactamases and Their Bacterial Producers in Health Care Settings.

Authors:  Wenjing Wu; Yu Feng; Guangmin Tang; Fu Qiao; Alan McNally; Zhiyong Zong
Journal:  Clin Microbiol Rev       Date:  2019-01-30       Impact factor: 26.132

5.  Correlation between Acinetobacter baumannii Resistance and Hospital Use of Meropenem, Cefepime, and Ciprofloxacin: Time Series Analysis and Dynamic Regression Models.

Authors:  Rania Kousovista; Christos Athanasiou; Konstantinos Liaskonis; Olga Ivopoulou; George Ismailos; Vangelis Karalis
Journal:  Pathogens       Date:  2021-04-15

Review 6.  Colistin Resistance in Aeromonas spp.

Authors:  Luis Uriel Gonzalez-Avila; Miguel Angel Loyola-Cruz; Cecilia Hernández-Cortez; Juan Manuel Bello-López; Graciela Castro-Escarpulli
Journal:  Int J Mol Sci       Date:  2021-06-01       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.